Table 1.

Baseline characteristics of the patients with cutaneous leishmaniasis included in the trial and treated with Sb^v plus placebo or Sb^v plus pentoxifylline

Characteristics	Sbv + placebo (82)	Sbv + pentoxifylline (82)
Sex (% of male)	72	63
Age (years) (M ± SD)	33.4 ± 11.2	33.3 ± 10.4
Number of lesions (M ± SD)	1.3 ± 0.6	1.3 ± 0.7
Area of lesions (mm2) (M ± SD)	132 ± 227	134 ± 249.3
Lesions in inferior limbs (%)	82	74
LST (area) (mm2) (M ± SD)	254.8 ± 133.3	252 ± 138.7

LST = Leishmania skin test; M = media; Sb^v = pentavalent antimony; SD = standard deviation.